One of the events on Cramer's radar this week was the kickoff of the JPMorgan healthcare conference. He can always count on new information being revealed, and get a good sense of how the health industry is doing.
At the meeting the Cramer fave speculative biotech company, Acorda Therapeutics announced stronger than expected sales figures for its drug Ampyra. This is a drug that enables multiple sclerosis patients with the ability to walk, and is being tested for the use with stroke victims and those with cerebral palsy.
To learn more about the future of Ampyra, Cramer spoke with Acorda CEO Ron Cohen who explained that it takes time for a drug such as Ampyra to penetrate the market.
"This was blazing new trails. There had never been a medication to improve walking before we were approved in 2010… and after a while people get educated and make that transition where it is now standard of care," Cohen said.
Another Cramer fave biotech is NPS Pharmaceuticals, up 45 percent in the past month. Wowzer!
On Sunday, Ireland-based Shire PLC agreed to acquire NPS Pharma for an all cash deal of $5.2 billion, or $46 a share.
Cramer started recommending NPS back in October 2012, when the stock was trading at $8.24. It now trades at $45, and the "Mad Money" host said it's time to ring the register on this hot biotech play.
To learn more, Cramer sat down with NPS Pharmaceuticals CEO Dr. Francois Nader.
"It will be a bumpy ride, and it's absolutely not a linear growth. Remember, it is one patient at a time; every patient counts. So some quarters you have many more patients and others you don't. What you need to look at is the trend, and not really at the point-per-point basis," he said.
Read More Cramer: Ring the register on this hot biotech play
Zimmer Holdings: "I think Zimmer is going higher. I like Edwards Lifesciences, I like Zimmer. I think these are the sweet spots in this marketplace. I know they're up a lot, maybe they come in and then you pull the trigger.
British Petroleum: "Don't short it, or you've got to pay that dividend. But I don't want to own BP, it's got too much risk there. Way too much risk."
Read More Lightning Round: Sweet spots of the marketplace